Agilex Biolabs
The Clinical Trial Biolabs Leaders

Bioanalytical technologies were crucial in mitigating the widespread effects of COVID-19 and promise to continue being critical in preventing any such outbreaks in the future. Bioanalytical testing services cater to pharmaceutical firms to ensure the safety and efficacy of medication compounds. The use of bioanalytical technique validation to ensure the trustworthiness of pharmacokinetic (PK) data has grown in popularity over the last few decades. Such validation programs have a well-established role in academics, business, and medical regulatory bodies. Bioanalytical testing services for small and big compounds have become increasingly popular among contract research organisations (CRO). With the contributions of companies such as Agilex Biolabs, the growing role of bioanalytical testing with good accuracy and precision, specificity, and sensitivity in drug development programs has also shaped the contours of the market.
There are significant challenges in using bioanalysis techniques for macromolecules and small molecules. It attracts pharma companies in the bioanalytical testing services market who have been consolidating their biologic drug pipelines. Such concerns have spurred CROs and service providers to look for better methods, characteristically that are based on good laboratory practice (GLP) and good clinical practice (GCP). And to cater to the needs, Aglix Biolabs aids platforms used for the quantification of macromolecules. The company does so by providing critical insights into the understanding of the PK/PD relationship in the clinical stages of a drug’s development.

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers, and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, GyrolabxPloreTM, Luminex), and flow cytometry (BD FACSymphony A3 20 colour cell analyser). With over 25 years of experience supporting pre-clinical and clinical programs, Agilex Biolabs’s operational scale ensures analytical results comply with the global industry standard for Bioanalytical CROs, providing data output in multiple formats.

The growing importance of bioanalytical testing with good accuracy and precision, specificity, and sensitivity in drug development programs has created more advancements in this global marketplace. And leading scientists at Agilex Biolabs take a multi-tiered approach to create either exploratory, qualified, or validated assays to support the entire life cycle of a clinical program. Their expertise includes Peptides/Proteins by LC-MS/MS/ Small Molecules NCEs, sugars, nucleotides, enantiomers, steroids, prodrugs, peptides, immunosuppressants, nanoparticles, neurotransmitters, and polymeric mixtures.

The capability to assay peptides or proteins using immunocapture techniques, protein MS, PK analysis, PD analysis, and biomarkers is no match to any of the competitors of Agilex Biolabs. In addition, clients of Agilex Biolabs have access to GALEXI, an innovative client portal that provides secure and enhanced communications globally. GALEXI supports researchers with real-time study management and cross-time zone transparency, allowing multinational clients to get information when they need it. TetraQ toxicology, a subsidiary of Agilex Biolabs, provides toxicological services. The toxicology team has over 15 years of expertise performing in-life trials with clients from universities and the biotech industries.

Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies such as Sciex API 6500+, LC-MS/MS systems, Sciex API 4000, LC-MS/MS systems, and Gyrolab Xplore. Agilex Biolabs uses world-class platform technologies to deliver speedy, precise, and robust test results to clients, ensuring the highest level of scientific innovation, customer service, data integrity, and quality assurance.